Co-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, from September 22-25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, from September 22-25, 2021. The presentation is scheduled for September 23 at 14:50 local time. The Company's Logix Smart™ COVID-19 Tests will be used for on-site testing of attendees, highlighting its expanding presence in Europe. Co-Diagnostics aims to engage with both new and existing customers to showcase its diagnostic products. Interested European distributors and laboratories can contact the Company for more information.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was +2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenting at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, held on September 22-25, 2021.
Co-Diagnostics' Logix Smart™ COVID-19 Tests have also been selected to be used for on-site testing for conference attendees, following recent and ongoing efforts to strengthen the Company's presence and distribution reach across the continent.
In addition to the presentation, which will be conducted at 14:50 local time on Thursday, September 23rd, Co-Diagnostics representatives expect to meet with new and existing customers and showcase the products available for sale in the region. European distributors or laboratories interested in learning more about these products may contact the Company at info@codiagnostics.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-actc-liquid-biopsy-conference-in-kalamata-greece-301381915.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.